FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Thomas

Research Profile

Concepts & Ideas

Procedures

Disorders

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Anne M Traynor; James P Thomas; Ramesh K Ramanathan; Tarak D Mody; Dona Alberti; George Wilding; Howard H Bailey
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
Brian S Choi; Dona Alberti; William R Schelman; Jill M Kolesar; James P Thomas; Rebecca Marnocha; Jens Eickhoff; S Percy Ivy; George Wilding; Kyle D Holen
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Sam J Lubner; Noelle K Loconte; Kyle D Holen; William R Schelman; James P Thomas; Alcee Jumonville; Jens Eickhoff; Songwon Seo; Daniel Mulkerin
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Thomas (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Anne M Traynor; James P Thomas; Ramesh K Ramanathan; Tarak D Mody; Dona Alberti; George Wilding; Howard H Bailey
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies.
Investigational new drugs 2011;29(2):316-22.
2010: Brian S Choi; Dona Alberti; William R Schelman; Jill M Kolesar; James P Thomas; Rebecca Marnocha; Jens Eickhoff; S Percy Ivy; George Wilding; Kyle D Holen
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2010;66(5):973-80.
2010: Sam J Lubner; Noelle K Loconte; Kyle D Holen; William R Schelman; James P Thomas; Alcee Jumonville; Jens Eickhoff; Songwon Seo; Daniel Mulkerin
A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer.
Clinical colorectal cancer 2010;9(3):157-61.
2010: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Jordan D Berlin; J Michael Berry; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Eric Rohren; David P Ryan; Leonard B Saltz; David Shibata; John M Skibber; William Small; Constantinos T Sofocleous; James P Thomas; Alan P Venook; Christopher Willett
NCCN clinical practice guidelines in oncology. Anal carcinoma.
Journal of the National Comprehensive Cancer Network : JNCCN 2010;8(1):106-20.
2009: Daniel Mulkerin; N K LoConte; K D Holen; James P Thomas; Dona Alberti; Rebecca Marnocha; Jill M Kolesar; Jens Eickhoff; K Oliver; Chris Feierabend; George Wilding
A phase I study of an oral simulated FOLFOX with high dose capecitabine.
Investigational new drugs 2009;27(5):461-8.
2009: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard B Saltz; David Shibata; John M Skibber; Constantinos T Sofocleous; James P Thomas; Alan P Venook; Christopher Willett
NCCN Clinical Practice Guidelines in Oncology: rectal cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(8):838-81.
2009: Paul F Engstrom; Juan Pablo Arnoletti; Al B Benson; Yi-Jen Chen; Michael A Choti; Harry S Cooper; Anne Covey; Raza A Dilawari; Dayna S Early; Peter C Enzinger; Marwan G Fakih; James Fleshman; Charles Fuchs; Jean L Grem; Krystyna Kiel; James A Knol; Lucille A Leong; Edward Lin; Mary F Mulcahy; Sujata Rao; David P Ryan; Leonard B Saltz; David Shibata; John M Skibber; Constantinos T Sofocleous; James P Thomas; Alan P Venook; Christopher Willett
NCCN Clinical Practice Guidelines in Oncology: colon cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(8):778-831.
2009: Brett E Fortune; Xiaobai Li; Kavitha V Kosuri; Lynn M Weatherby; James P Thomas; Tanios S Bekaii-Saab
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Oncology 2009;76(5):333-7.
2008: Noelle K LoConte; James P Thomas; Dona Alberti; Jennifer Heideman; Kim Binger; Rebecca Marnocha; Kyle Utecht; Peter Geiger; Jens Eickhoff; George Wilding; Jill M Kolesar
A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2008;63(1):109-15.
2008: Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Heidi Nelson; Renaud Whittom; Alexander Hantel; James P Thomas; Charlie S Fuchs
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(25):4109-15.
2008: William Schelman; Sherry Morgan-Meadows; Howard H Bailey; Kyle Holen; James P Thomas; Jens Eickhoff; Heidi Brandon; Kate Oliver; Dona Alberti; George Wilding
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2008;62(4):727-33.
2008: Jennifer A Chan; Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James P Thomas; Paul Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Robert S Warren; Monica Bertagnolli; Charlie S Fuchs
Association of family history with cancer recurrence and survival among patients with stage III colon cancer.
JAMA : the journal of the American Medical Association 2008;299(21):2515-23.
2008: Emily Chan; Daniel Mulkerin; Mace Rothenberg; Kyle D Holen; A Craig Lockhart; James P Thomas; Jordan Berlin
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Investigational new drugs 2008;26(3):241-7.
2008: Jill M Kolesar; William R Schelman; Peter G Geiger; Kyle D Holen; Anne M Traynor; Dona B Alberti; James P Thomas; Christopher R Chitambar; George Wilding; William E Antholine
Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid tumors treated with Triapine.
Journal of inorganic biochemistry 2008;102(4):693-8.
2008: Steven Attia; Kyle D Holen; James P Thomas; Kelly Richie; Torie Dzelak; Kristine Teeter; Deb Warren; Andrea Bilger; Jason P Fine; Jens Eickhoff; Norman Drinkwater; Daniel Mulkerin; Sherry Morgan-Meadows
Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Clinical advances in hematology & oncology : H&O 2008;6(1):44-54.
2007: Jeffrey A Meyerhardt; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Frank B Hu; Robert J Mayer; Heidi Nelson; Renaud Whittom; Alexander Hantel; James P Thomas; Charlie S Fuchs
Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer.
JAMA : the journal of the American Medical Association 2007;298(7):754-64.
2007: Leonard B Saltz; Donna Niedzwiecki; Donna Hollis; Richard M Goldberg; Alexander Hantel; James P Thomas; Anthony L A Fields; Robert J Mayer
Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3456-61.
2007: Howard H Bailey; Dona Alberti; James P Thomas; Daniel Mulkerin; Kim Binger; Marco Gottardis; Robert E Martell; George Wilding
Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3623-9.
2006: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James P Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charlie S Fuchs
Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3535-41.
2006: Philip A Philip; Michelle R Mahoney; Cristine Allmer; James P Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom R Fitch; Joel Picus; Charles Erlichman
Phase II study of erlotinib in patients with advanced biliary cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3069-74.
2005: Michael Huie; Michael A Carducci; Glenn Liu; George Wilding; Rebecca Marnocha; Miguel Izquierda; James P Thomas
Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors.
American journal of clinical oncology 2005;28(6):613-7.
2005: Douglas G McNeel; Jens Eickhoff; Fred T Lee; David M King; Dona Alberti; James P Thomas; Andreas Friedl; Jill M Kolesar; Rebecca Marnocha; Jennifer Volkman; Jianliang Zhang; Luz D Hammershaimb; James A Zwiebel; George Wilding
Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7851-60.
2005: Philip A Philip; Michelle R Mahoney; Cristine Allmer; James P Thomas; Henry C Pitot; George Kim; Ross C Donehower; Tom R Fitch; Joel Picus; Charles Erlichman
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(27):6657-63.
2005: Grace K Dy; James P Thomas; George Wilding; Laura M Bruzek; Sumithra J Mandrekar; Charles Erlichman; Dona Alberti; Kim Binger; Henry C Pitot; Steven R Alberts; Lorelei J Hanson; Rebecca Marnocha; Kendra Tutsch; Scott H Kaufmann; Alex A. Adjei
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3410-6.
2005: Sherry Morgan-Meadows; Daniel Mulkerin; Jordan D Berlin; KyungMann Kim; Howard H Bailey; Thomas Saphner; Alcee Jumonville; Richard Hansen; Harish Ahuja; Thomas McFarland; James P Thomas
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Oncology 2005;69(2):130-4.
2004: Robert C Shepard; Donna E Levy; Jordan D Berlin; Keith Stuart; Jules E Harris; Victor Aviles; James P Thomas; Al B Benson
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Oncology 2004;66(4):303-9.
2003: Glenn Liu; Howard H Bailey; Rhoda Arzoomanian; Dona Alberti; Kim Binger; Jennifer Volkman; Chris Feierabend; Rebecca Marnocha; George Wilding; James P Thomas
Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
American journal of clinical oncology 2003;26(3):280-4.
2003: James P Thomas; Rhoda Arzoomanian; Dona Alberti; Rebecca Marnocha; Fred Lee; Andreas Friedl; Kendra Tutsch; Amy Dresen; Peter Geiger; James Pluda; William Fogler; Joan H Schiller; George Wilding
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(2):223-31.
2002: James P Thomas; Kendra Tutsch; James F Cleary; Howard H Bailey; Rhoda Arzoomanian; Dona Alberti; Kris Simon; Chris Feierabend; Kim Binger; Rebecca Marnocha; Amy Dresen; George Wilding
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Cancer chemotherapy and pharmacology 2002;50(6):465-72.
2002: Sherry Morgan-Meadows; James P Thomas; Daniel Mulkerin; Jordan D Berlin; Howard H Bailey; Kim Binger; Jennifer Volkman; Dona Alberti; Chris Feierabend; Rebecca Marrocha; Rhoda Arzoomanian; George Wilding
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Investigational new drugs 2002;20(4):377-82.
2002: Jordan D Berlin; Paul J Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al B Benson
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(15):3270-5.
2002: Joseph Merchant; Kendra Tutsch; Amy Dresen; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kim Binger; Rebecca Marnoccha; James P Thomas; Jim Cleary; George Wilding
Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2193-201.
2002: Sherry Morgan Meadows; Daniel Mulkerin; Jordan Berlin; Howard H Bailey; Jill M Kolesar; Deb Warren; James P Thomas
Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer.
International journal of gastrointestinal cancer 2002;32(2-3):125-8.
2001: James P Thomas; Rhoda Arzoomanian; Dona Alberti; Chris Feierabend; Kim Binger; Kendra Tutsch; T Steele; Rebecca Marnocha; C Smith; S Smith; J MacDonald; George Wilding; Howard H Bailey
Phase I clinical and pharmacokinetic trial of irofulven.
Cancer chemotherapy and pharmacology 2001;48(6):467-72.
2001: Christoph Mundhenke; James P Thomas; George Wilding; Fred T Lee; F Kelzc; Richard J Chappell; R Neider; L A Sebree; Andreas Friedl
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3366-74.
2001: James P Thomas; AI Porcell; A L Sagone
Splenic angiosarcoma and iron deficiency anemia in a 43-year-old man.
Southern medical journal 2001;94(6):640-3.
2001: PP Carbone; J D Pirsch; James P Thomas; Jeffrey A Douglas; AK Verma; Paul O Larson; Stephen N Snow; Kendra Tutsch; D Pauk
Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(6):657-61.
2000: PP Carbone; Jeffrey A Douglas; James P Thomas; Kendra Tutsch; Marcia Pomplun; M Hamielec; D Pauk
Bioavailability study of oral liquid and tablet forms of alpha-difluoromethylornithine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(10):3850-4.